By Counterforce Health Team in Evrysdi (risdiplam) —

Myths vs. Facts: Getting Evrysdi (Risdiplam) Covered by UnitedHealthcare in Pennsylvania - Appeals Guide 2025

Answer Box: Getting Evrysdi Covered by UnitedHealthcare in Pennsylvania

Eligibility: UnitedHealthcare requires prior authorization for Evrysdi with genetic confirmation of SMA, SMN2 copy documentation (2-4 copies for symptomatic patients), and baseline motor function assessments. No step therapy required, but concurrent use with Spinraza is prohibited.

Fastest Path: Submit complete PA request via UnitedHealthcare Provider Portal with genetic testing results, motor assessments, and prescriber attestation from SMA-experienced neurologist. OptumRx responds within 15 days (72 hours for urgent cases).

First Step Today: If denied, file internal appeal within 180 days. Pennsylvania's external review program overturns 50%+ of denials - request within 4 months of final denial at pa.gov/reviewmyclaim.

Table of Contents

  1. Why Myths About Evrysdi Coverage Persist
  2. Myth vs. Fact: Common Misconceptions
  3. What Actually Influences UnitedHealthcare Approval
  4. Avoid These Critical Mistakes
  5. Quick Action Plan: Three Steps to Take Today
  6. Pennsylvania-Specific Appeals Process
  7. Financial Assistance Programs
  8. FAQ
  9. Sources & Resources

Why Myths About Evrysdi Coverage Persist

Navigating Evrysdi (risdiplam) coverage through UnitedHealthcare can feel overwhelming, especially when misinformation spreads through patient communities and even some healthcare offices. These myths persist because SMA treatments are relatively new, insurance policies change frequently, and the high cost—up to $340,000 annually—makes everyone anxious about coverage decisions.

The reality is that UnitedHealthcare has specific, documented criteria for Evrysdi approval that, when met properly, lead to consistent coverage. Understanding these facts versus fiction can save you months of delays and unnecessary stress.

Myth vs. Fact: Common Misconceptions

Myth 1: "If my neurologist prescribes Evrysdi, UnitedHealthcare must cover it"

Fact: UnitedHealthcare requires prior authorization regardless of who prescribes Evrysdi. Even prescriptions from leading SMA specialists at major medical centers need PA approval through OptumRx. The prescriber must be experienced in SMA management, but their reputation alone doesn't guarantee coverage.

Myth 2: "I need to try Spinraza first because of step therapy requirements"

Fact: UnitedHealthcare does not require step therapy for Evrysdi. However, you cannot receive Evrysdi while actively taking Spinraza (nusinersen) or other chronic SMN-modifying therapies. If you've previously tried and failed Spinraza, that actually supports your Evrysdi approval.

Myth 3: "Genetic testing from years ago is sufficient for approval"

Fact: UnitedHealthcare requires current, comprehensive genetic documentation including both SMN1 deletion/mutation status and specific SMN2 copy numbers (2-4 copies for symptomatic patients, 2-3 for pre-symptomatic). Old genetic reports may lack SMN2 copy number details that are now mandatory.

Myth 4: "If I'm denied once, I can't get approved later"

Fact: Pennsylvania's external review program overturned over 50% of health insurance denials in 2024. You have multiple appeal levels: internal appeals (180-day deadline), and external review through Pennsylvania's Independent Review Organization (4-month deadline after final denial).

Myth 5: "UnitedHealthcare won't cover Evrysdi because it's too expensive"

Fact: Cost alone cannot be a denial reason if medical necessity criteria are met. UnitedHealthcare regularly covers Evrysdi when proper documentation is submitted, including genetic confirmation, motor function assessments, and prescriber attestation.

Myth 6: "I need to prove financial hardship to get coverage"

Fact: Medical necessity, not financial need, determines UnitedHealthcare coverage. Financial assistance programs like Genentech's copay program (up to $25,000 annually) help with out-of-pocket costs after insurance approval, but they're separate from coverage decisions.

Myth 7: "Appeals take forever and rarely work"

Fact: UnitedHealthcare internal appeals have specific timelines (typically 30 days for standard, 72 hours for urgent), and Pennsylvania's external review process decides standard cases within 45 days, expedited within 72 hours. Success rates for well-documented appeals are significantly higher than many patients realize.

What Actually Influences UnitedHealthcare Approval

Required Documentation Checklist

Genetic Testing Requirements:

  • Confirmed SMN1 gene deletion or pathogenic variants (both copies affected)
  • SMN2 copy number documentation (2-4 copies for symptomatic, 2-3 for pre-symptomatic)
  • Results from certified laboratory

Clinical Documentation:

  • Baseline motor function assessment using validated tools (CHOP-INTEND, HFMSE, HINE-2)
  • Age verification (typically ≤25 years, ≥2 months)
  • SMA diagnosis with ICD-10 codes
  • Documentation of previous SMA treatments and outcomes

Prescriber Requirements:

  • Prescription from neurologist experienced in SMA treatment
  • Medical necessity letter explaining treatment rationale
  • Attestation of patient monitoring plan

Coverage Decision Factors

UnitedHealthcare's approval algorithm considers:

  1. Medical necessity criteria compliance - all required documentation submitted
  2. Previous authorization history - prior approvals for SMA treatments
  3. Diagnosis coding accuracy - proper ICD-10 codes for SMA type
  4. Prescriber credentials - experience with SMA management
  5. Treatment history - documentation of failed alternatives (if applicable)

Avoid These Critical Mistakes

1. Incomplete Genetic Testing Documentation

Problem: Submitting old genetic reports without SMN2 copy numbers Solution: Request comprehensive genetic panel including both SMN1 and SMN2 analysis from certified lab

2. Missing Motor Function Baselines

Problem: No documented baseline motor assessments Solution: Complete age-appropriate motor function testing (CHOP-INTEND for infants, HFMSE for ambulatory patients) before PA submission

3. Inadequate Prescriber Documentation

Problem: Generic prescription without medical necessity justification Solution: Detailed letter from neurologist explaining diagnosis, previous treatments, expected outcomes, and monitoring plan

4. Wrong Appeal Timing

Problem: Missing Pennsylvania's 4-month external review deadline Solution: Calendar all deadlines immediately upon denial - 180 days for internal appeal, 4 months for external review after final denial

5. Incomplete Financial Assistance Applications

Problem: Assuming insurance denial means no treatment access Solution: Apply for Genentech patient assistance programs simultaneously with insurance appeals

Quick Action Plan: Three Steps to Take Today

Step 1: Gather Complete Documentation (Today)

  • Request comprehensive genetic testing results including SMN2 copy numbers
  • Schedule motor function assessment if not completed within 6 months
  • Obtain detailed medical records from all previous SMA treatments

Step 2: Submit Thorough PA Request (Within 1 Week)

  • Use UnitedHealthcare Provider Portal for submission
  • Include all required documentation in single submission to avoid delays
  • Request expedited review if treatment delay could cause harm

Step 3: Prepare for Potential Appeal (Within 2 Weeks)

  • Enroll in MySMA Support Program for insurance navigation assistance
  • Document all communication with UnitedHealthcare with dates and reference numbers
  • Research Pennsylvania external review process at pa.gov/reviewmyclaim

Pennsylvania-Specific Appeals Process

Internal Appeals with UnitedHealthcare

  • Deadline: 180 days from denial date
  • Timeline: 30 days for standard review, 72 hours for urgent
  • Submission: Provider portal, fax, or mail with all supporting documentation
  • Expedited Appeals: Address to UnitedHealthcare Fast Grievance, P.O. Box 6103, MS CA120-0360, Cypress, CA 90630-0023

Pennsylvania External Review Program

Pennsylvania's Independent External Review Program offers significant advantages:

Success Rate: Over 50% of appeals overturned in 2024 Eligibility: Commercial insurance plans (not self-funded employer plans) Timeline: 45 days standard, 72 hours expedited Cost: Free to consumers Process: Submit at pa.gov/reviewmyclaim or call 1-877-881-6388

From Our Advocates: We've seen families successfully overturn Evrysdi denials by submitting comprehensive genetic testing with SMN2 copy numbers and detailed motor function assessments. The key is ensuring your neurologist documents not just the diagnosis, but the specific clinical rationale for why Evrysdi is medically necessary for your situation. This composite experience shows that thorough documentation significantly improves approval odds.

Financial Assistance Programs

Genentech Copay Assistance

  • Benefit: Up to $25,000 annually for commercially insured patients
  • Eligibility: Age 18+, commercial insurance, no financial need requirement
  • Application: evrysdicopay.com or call 833-387-9734
  • Coverage: May reduce copay to $0 per prescription

Free Drug Programs

  • Genentech Patient Foundation: Free Evrysdi for uninsured/underinsured patients with financial hardship
  • MySMA Support: Insurance navigation, appeals assistance, and foundation referrals
  • Enrollment: Required for assistance but automatic qualification review

Coverage Gap Solutions

  • Evrysdi Start Program: Temporary free medication during insurance delays
  • Pennsylvania Health Law Project: Free legal assistance for appeals (1-800-274-3258)

At Counterforce Health, we help patients and clinicians turn insurance denials into successful appeals by analyzing denial letters, identifying specific coverage criteria, and drafting evidence-backed rebuttals that align with each payer's requirements. Our platform streamlines the complex appeals process, helping families get the treatments they need faster.

FAQ

How long does UnitedHealthcare prior authorization take for Evrysdi in Pennsylvania? OptumRx typically responds within 15 calendar days for standard requests, 72 hours for urgent cases requiring expedited review.

What if Evrysdi isn't on my UnitedHealthcare formulary? Non-formulary status doesn't prevent coverage if medical necessity is established. Request formulary exception with comprehensive clinical documentation.

Can I request expedited appeal if my child's condition is worsening? Yes, urgent medical situations qualify for expedited review (72-hour decision timeline) through both UnitedHealthcare internal appeals and Pennsylvania external review.

Does step therapy apply if I've never tried other SMA treatments? No, UnitedHealthcare does not require step therapy for Evrysdi. However, document any contraindications to alternative treatments in your PA request.

What happens if Pennsylvania external review overturns my denial? The decision is binding - UnitedHealthcare must provide coverage immediately, including retroactive coverage if you paid out-of-pocket during appeals.

How do I know if my employer plan is eligible for Pennsylvania external review? Self-funded employer plans are not eligible. Ask your HR department or check your plan documents for "self-funded" or "ERISA" language.

Sources & Resources

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and requirements may change. Always verify current requirements with UnitedHealthcare and consult with your healthcare provider for medical decisions. For official Pennsylvania insurance assistance, contact the Pennsylvania Insurance Department at 1-877-881-6388.

Whether you're just starting the prior authorization process or facing a denial, Counterforce Health provides the tools and expertise to help navigate complex insurance requirements and improve your chances of getting Evrysdi covered through evidence-based appeals.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.